PepGen Shares Rise After Positive Results in PGN-EDO51 Trial

Dow Jones

Sep 28, 2022

By Chris Wack

PepGen Inc. shares were up 19%, to $6.17, after the company said it saw positive results from its completed trial of PGN-EDO51, its lead product candidate for the treatment of certain Duchenne Muscular Dystrophy patients.

The biotechnology company's Phase 1 HNV trial of PGN-EDO51 was a single ascending dose clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males. Oligonucleotide tissue concentration and exon skipping also were assessed.

The trial met its primary endpoint assessing the safety profile of PGN-EDO51 at pharmacologically relevant doses. PGN-EDO51 was generally well tolerated.

PepGen now plans to begin a Phase 2a multiple ascending dose clinical trial in DMD patients in the first half of 2023.

All participants completed the trial; there were no discontinuations. The majority of treatment-emergent adverse events were assessed as mild and resolved without any intervention. At 10 mg/kg, there were only Grade 1 adverse events.

The stock hit its 52-week low of $4.32 last Friday, and is down 48% in the last three months.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

September 28, 2022 10:00 ET (14:00 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2270787635"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2270787635\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2270787635?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-28 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2270787635","market":"hk","top_or_hot":-1,"title":"PepGen Shares Rise After Positive Results in PGN-EDO51 Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PEPG\">PepGen Inc.</a> shares were up 19%, to $6.17, after the company said it saw positive results from its completed trial of PGN-EDO51, its lead product candidate for the treatment of certain Duchenne Muscular Dystrophy patients. \n</p>\n<p>\n  The biotechnology company's Phase 1 HNV trial of PGN-EDO51 was a single ascending dose clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males. Oligonucleotide tissue concentration and exon skipping also were assessed. \n</p>\n<p>\n  The trial met its primary endpoint assessing the safety profile of PGN-EDO51 at pharmacologically relevant doses. PGN-EDO51 was generally well tolerated. \n</p>\n<p>\n  PepGen now plans to begin a Phase 2a multiple ascending dose clinical trial in DMD patients in the first half of 2023. \n</p>\n<p>\n  All participants completed the trial; there were no discontinuations. The majority of treatment-emergent adverse events were assessed as mild and resolved without any intervention. At 10 mg/kg, there were only Grade 1 adverse events. \n</p>\n<p>\n  The stock hit its 52-week low of $4.32 last Friday, and is down 48% in the last three months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 28, 2022 10:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PepGen Shares Rise After Positive Results in PGN-EDO51 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPepGen Shares Rise After Positive Results in PGN-EDO51 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-09-28 22:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PEPG\">PepGen Inc.</a> shares were up 19%, to $6.17, after the company said it saw positive results from its completed trial of PGN-EDO51, its lead product candidate for the treatment of certain Duchenne Muscular Dystrophy patients. \n</p>\n<p>\n  The biotechnology company's Phase 1 HNV trial of PGN-EDO51 was a single ascending dose clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males. Oligonucleotide tissue concentration and exon skipping also were assessed. \n</p>\n<p>\n  The trial met its primary endpoint assessing the safety profile of PGN-EDO51 at pharmacologically relevant doses. PGN-EDO51 was generally well tolerated. \n</p>\n<p>\n  PepGen now plans to begin a Phase 2a multiple ascending dose clinical trial in DMD patients in the first half of 2023. \n</p>\n<p>\n  All participants completed the trial; there were no discontinuations. The majority of treatment-emergent adverse events were assessed as mild and resolved without any intervention. At 10 mg/kg, there were only Grade 1 adverse events. \n</p>\n<p>\n  The stock hit its 52-week low of $4.32 last Friday, and is down 48% in the last three months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 28, 2022 10:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEPG","symbol_name":"PepGen Inc.","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2270787635","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2270787635","pubTimestamp":1664373600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"By Chris Wack \n\n\n \n\n\nPepGen Inc. shares were up 19%, to $6.17, after the company said it saw positiv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEPG":"PepGen Inc."},"translate_title":"PGN-EDO51试验结果呈阳性后PepGen股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEPG":0.9,"PGN":1},"content_text":"By Chris Wack \n\n\n \n\n\nPepGen Inc. shares were up 19%, to $6.17, after the company said it saw positive results from its completed trial of PGN-EDO51, its lead product candidate for the treatment of certain Duchenne Muscular Dystrophy patients. \n\n\n  The biotechnology company's Phase 1 HNV trial of PGN-EDO51 was a single ascending dose clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males. Oligonucleotide tissue concentration and exon skipping also were assessed. \n\n\n  The trial met its primary endpoint assessing the safety profile of PGN-EDO51 at pharmacologically relevant doses. PGN-EDO51 was generally well tolerated. \n\n\n  PepGen now plans to begin a Phase 2a multiple ascending dose clinical trial in DMD patients in the first half of 2023. \n\n\n  All participants completed the trial; there were no discontinuations. The majority of treatment-emergent adverse events were assessed as mild and resolved without any intervention. At 10 mg/kg, there were only Grade 1 adverse events. \n\n\n  The stock hit its 52-week low of $4.32 last Friday, and is down 48% in the last three months. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 28, 2022 10:00 ET (14:00 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}